| Thymoma, myasthenia gravis, and other paraneoplastic syndromes. | |
| | |
MedLine Citation:
|
PMID: 18514130 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The relationship between myasthenia gravis and thymic pathology, including thymoma, is well known. Approximately 10% to 15% of patients who have myasthenia gravis are observed to have a thymoma. Myasthenia gravis may be considered as the most common of the paraneoplastic syndromes in patients who have thymoma. This article summarizes the clinical aspects of myasthenia gravis, followed by a review of the less often recognized paraneoplastic disorders noted to occur in patients who have thymoma. |
| | |
Authors:
|
Laura M Tormoehlen; Robert M Pascuzzi |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Hematology/oncology clinics of North America Volume: 22 ISSN: 0889-8588 ISO Abbreviation: Hematol. Oncol. Clin. North Am. Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-06-02 Completed Date: 2008-08-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8709473 Medline TA: Hematol Oncol Clin North Am Country: United States |
Other Details:
|
Languages: eng Pagination: 509-26 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Indiana University School of Medicine, Emerson Hall Room 125, 545 Barnhill Drive, Indianapolis, IN 46202, USA. laumjone@iupui.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cholinesterase Inhibitors
/
therapeutic use Humans Immunosuppressive Agents Myasthenia Gravis / complications*, diagnosis, therapy Paraneoplastic Syndromes / complications* Thymectomy / adverse effects Thymoma / complications* Thymus Neoplasms / complications* |
| Chemical | |
Reg. No./Substance:
|
0/Cholinesterase Inhibitors; 0/Immunosuppressive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Radiotherapy for thymoma and thymic carcinoma.
Next Document: Prognostic factors for thymic epithelial neoplasms, with emphasis on tumor staging.